Research programme: cancer metabolism therapeutics - Agios/CelgeneAlternative Names: AGI-14100; Glutaminase - Agios/Celgene; isocitrate dehydrogenase inhibitors - Agios/Celgene
Latest Information Update: 16 Jul 2016
At a glance
- Originator Agios Pharmaceuticals
- Class Small molecules
- Mechanism of Action Glutamine inhibitors; Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors; Phosphofructokinase modulators; Pyruvate kinase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
- Research Cancer
- No development reported Brain cancer